Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Withdrawn 2Unknown 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 3Other hematologic neoplasm 2Head & Neck 2Thoracic 1Sarcoma 1Myeloid 1Lymphoid 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 86Cyclophosphamide 67Capecitabine 67Paclitaxel 63Docetaxel 57Fulvestrant 52Letrozole 50Carboplatin 42pembrolizumab 40Lapatinib 38Doxorubicin 36Anastrozole 32Vinorelbine 31Bevacizumab 31exemestane 28Tamoxifen 25Gemcitabine 25Albumin-Bound Paclitaxel 25Radiotherapy 21Taxes 18atezolizumab 17Everolimus 17130-nm albumin-bound paclitaxel 17pertuzumab 16Epirubicin 16palbociclib 15eribulin 14Magnetic Resonance Spectroscopy 14Ado-Trastuzumab Emtansine 14Goserelin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Reverse Transcriptase Polymerase Chain Reaction × Breast × Clear all
NCT00665457 2023-09-13

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

University of Nebraska

Phase 2 Terminated
3 enrolled 6 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡